ArticleNature medicine2009
Copy number analysis indicates monoclonal origin of lethal metastatic prostate cancer.
Article in Nature medicine, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 349 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
349 citing papers in PubMed, 2 syntheses or guidelines pooled it, 657 citations in OpenAlex.
- Focal radiation therapies for localized prostate cancer: a systematic review of clinical evidence and outcomes.Prostate cancer and prostatic diseases · 2026Pooled it
- The role of focal therapy in the management of localised prostate cancer: a systematic review.European urology · 2014Pooled it
- Circulating tumor DNA profile recognizes transformation to castration-resistant neuroendocrine prostate cancer.The Journal of clinical investigation · 2020Trial
- Multiregion ultra-deep sequencing reveals early intermixing and variable levels of intratumoral heterogeneity in colorectal cancer.Molecular oncology · 2017Trial
- A prospective clinical trial of HIFU hemiablation for clinically localized prostate cancer.Prostate cancer and prostatic diseases · 2016Trial
- Improvements in Radiographic Progression-Free Survival Stratified by ERG Gene Status in Metastatic Castration-Resistant Prostate Cancer Patients Treated with Abiraterone Acetate.Clinical cancer research : an official journal of the American Association for Cancer Research · 2015Trial
- Uncovering genes driving developmental stage progression in prostate cancer through spatial transcriptomics.Genes & diseases · 2026Article
- De-escalation surgery for localized prostate cancer: rationale and future direction of precision prostatectomy.Current opinion in urology · 2026Review
- Inter- and intra-rater variability of MRI-based lesion size measurements in active surveillance for prostate cancer: a multicentre study.European radiology · 2026Article
- Recurrent intra-tumour heterogeneity is a hallmark of metastatic prostate cancer.Nature communications · 2026Article
- Bayesian inference of tissue-migration histories in metastatic cancer from cell-lineage tracing data.Cell genomics · 2026Article
- Advances in focal therapy for prostate cancer: current modalities, outcomes, and future directions.Prostate international · 2026Review
- Article
- Bridging to systemic therapy: PSMA-PET-based early and repetitive stereotactic body radiotherapy for nodal and bone oligo-recurrent prostate cancer.Frontiers in urology · 2026Article
- Image-Based Recurrence Patterns After Reirradiation in Prostate Cancer with Long-Term Follow-Up.Advances in radiation oncology · 2025Article
- Divergent Clonal Evolution and Early Dissemination Promote Genetic Heterogeneity of Metastases in Castration-Resistant Prostate Cancer.Cancer research · 2025Article
- Impact of Surgical Margin Control in Index Tumors on Prognosis After Radical Prostatectomy: A Focus on Zonal Origin.Current oncology (Toronto, Ont.) · 2025Article
- Uncovering phenotypic heterogeneity through research autopsy in lethal prostate cancer.The Journal of clinical investigation · 2025Article
- Patterns of intra- and intertumor phenotypic heterogeneity in lethal prostate cancer.The Journal of clinical investigation · 2025Article
- Identification of protein-coding genes associated with metastatic prostate cancer.Endocrine-related cancer · 2025Article
289 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
- Erratum issued
Authors and funding
18 authors at 6 institutions in 2 countries.
Funding
Abstract
Many studies have shown that primary prostate cancers are multifocal and are composed of multiple genetically distinct cancer cell clones. Whether or not multiclonal primary prostate cancers typically give rise to multiclonal or monoclonal prostate cancer metastases is largely unknown, although studies at single chromosomal loci are consistent with the latter case. Here we show through a high-resolution genome-wide single nucleotide polymorphism and copy number survey that most, if not all, metastatic prostate cancers have monoclonal origins and maintain a unique signature copy number pattern of the parent cancer cell while also accumulating a variable number of separate subclonally sustained changes. We find no relationship between anatomic site of metastasis and genomic copy number change pattern. Taken together with past animal and cytogenetic studies of metastasis and recent single-locus genetic data in prostate and other metastatic cancers, these data indicate that despite common genomic heterogeneity in primary cancers, most metastatic cancers arise from a single precursor cancer cell. This study establishes that genomic archeology of multiple anatomically separate metastatic cancers in individuals can be used to define the salient genomic features of a parent cancer clone of proven lethal metastatic phenotype.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.